Tuesday, November 14, 2023
12:00 pm – 1:00 pm CT / 1:00 pm – 2:00 pm ET
Register
Antimicrobial resistance remains a pertinent and growing challenge for healthcare professionals and has been designated among the top ten global public health threats facing humanity by the World Health Organization. In the United States, carbapenem resistant Gram negative pathogens are ranked among the most urgent threats due to antibiotic resistance. Gram negative organisms employ complex resistance mechanisms that can lead to subsequent challenges in treatment. Questions regarding appropriate antimicrobial therapy remain, including combination versus monotherapy, dose optimization, and duration of treatment. To assist in the management of difficult-to-treat Gram negative bacterial infections, the IDSA published two guidance documents. However, real world examples are needed to help guide clinicians.
The goal of this webinar is to highlight real-world experiences by discussing new and emerging data concerning the management of the most challenging multidrug resistant Gram negative organisms, including those with carbapenem resistance. The presentation will be case-based and delivered by faculty with hands-on experience in treating these types of infections and enhanced with active learning engagement questions throughout followed by a live question & answer session.
Target Audience:
This activity is designed to mee the education needs of infectious diseases and critical care pharmacists. The educational content is also relevant for physicians, and advanced-practice providers involved in treating complex patients with carbapenem-resistant Gram negative infections.
Learning Objectives:
- Describe the spectrum of activity for contemporary Gram negative anti-infective agents used to treat seriously ill patients with carbapenem-resistant Gram negative infections.
- Utilize guidance documents and emerging data for treatment of carbapenem resistant Gram negative pathogens developed by the Infectious Diseases Society of America (IDSA) to develop a pragmatic approach to optimize antibiotic therapy.
- Compare and contrast benefits and challenges of using contemporary Gram negative anti-infective agents for treatment of infections caused by carbapenem resistant Gram negative organisms.
- Formulate a treatment regimen in patient-specific scenarios where evidence based literature is limited.
Faculty:
Tomefa E. Asempa, PharmD
Associate Director
Center For Anti-Infective Research and Development
Hartford Hospital
Hartford, CT
Barbara Santevecchi, PharmD, BCIDP
Clinical Assistant Professor, Infectious Diseases
Department of Pharmacotherapy and Translational Research
University of Florida College of Pharmacy/UF Health Shands Hospital
Gainesville, FL
Accreditation:
Pharmacist
The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0672-0000-23-046-L01-P
CPE credit: 1.0 contact hour (0.1 CEU)
Type of activity: Application
Activity Fee: Free
To receive CE credit, participants must attend the webinar, complete online a post-test with a passing score of 70% or greater and an activity evaluation. Proof of completion will be submitted to NABP CPE Monitor.
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Participants are responsible for verifying credits were transferred successfully to your NABP eProfile account before the ACPE 60-day deadline. After the 60 day deadline, SIDP will no longer be able to report your credit(s) for this activity.
Funding:
This webinar is supported by an unrestricted educational grant from Shionogi.
Disclosures:
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, SIDP asks all individuals involved in the development and presentation of CE activities to disclose all relevant financial relationships with ineligible companies. All relevant financial relationships have been mitigated prior to the CE activity. The following relevant financial relationships have been disclosed:
- Dr. Asempa received research funding from Shionogi, Paratek, Spero Therapeutics, and Venatorx.
- Dr. Santevecchi received research funding from Shionogi.
- SIDP planners, staff and other individuals who are in a position to control the content of this CE activity have no relevant financial relationships with an ineligible company to disclose.
Disclaimer:
Faculty members are asked to disclose when any unlabeled/investigational use of pharmaceuticals and devices is being discussed. This activity is intended for educational purposes and should not be used as a substitute for care or advice from a professional. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of SIDP.
The planners and faculty of this continuing education activity have made all reasonable efforts to ensure the accuracy of the information presented in accordance with the latest available scientific knowledge at the time of publication. Healthcare professionals should verify all information and data with recommendations of other authorities before treating patients or employing any therapies described in this continuing education activity.
Register
.gif){kind=logo}